Rise Advisors’s PTC Therapeutics PTCT Stock Holding History

Rise Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-184	Closed	-$11.3K	–	1112
2025 Q3	$11.3K	Hold	184	–	–	﹤0.01%	926
2025 Q2	$8.99K	Hold	184	–	–	﹤0.01%	1040
2025 Q1	$9.38K	Buy	+184	New	+$9.18K	﹤0.01%	1013

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rise Advisors's PTCT Position: Q4 2025 in Review

Rise Advisors sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 184 shares — an estimated $11.3K sold.

Rise Advisors first reported a position in PTCT in Q1 2025 and held it in 3 quarters. The position peaked at $11.3K in Q3 2025. 353 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.

Rise Advisors reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 184 PTC Therapeutics shares in Q4 2025, an estimated $11.3K.
Rise Advisors first reported a position in PTC Therapeutics in Q1 2025 and held it in 3 quarters.
Rise Advisors's PTC Therapeutics position peaked at $11.3K in Q3 2025.
353 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.